Semaglutide and GLP-1 Drugs for Fatty Liver (MASH): What the Evidence Shows in 2026
Semaglutide is now approved in India for MASH with F2–F3 fibrosis. Hepatologist Dr Chetan Kalal explains the ESSENCE results, tirzepatide and resmetirom, side effects and who qualifies.













